ArticleActa dermato-venereologica2026
Real-world Efficacy and Safety of Stapokibart in Children and Adolescents with Moderate-to-severe Atopic Dermatitis: A Retrospective Study.
Article in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paediatric real-world evidence for stapokibart in moderate-to-severe atopic dermatitis (AD) is scarce. We retrospectively analysed 55 patients aged 6-17 years treated at a single centre for 16 weeks using weight-tiered dosing (<30 kg: 600 mg loading, then 300 mg every 4 weeks; ≥30 kg: 600 mg loading, then 300 mg every 2 weeks). Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), body surface area (BSA), Investigator's Global Assessment (IGA), Children's Dermatology Life Quality Index (CDLQI) and Pruritus Numerical Rating Scale (P-NRS) were assessed at baseline and weeks 4, 8, 12 and 16. At week 16, median EASI fell from 10.0 to 1.95 and SCORAD from 46.2 to 13.3; P-NRS from 8.0 to 1.0 and CDLQI from 14.0 to 4.0. Week 16 response rates were 92.7% (EASI-50), 70.9% (EASI-75), 38.2% (EASI-90), 52.7% (IGA 0/1) and 67.3% (P-NRS≤2). Mild adverse events occurred in 9.1%. Stapokibart was associated with rapid improvements in disease severity, itch and quality of life and was well tolerated in routine paediatric care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.